Sood AK - Search Results

1

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.

Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK. Previs RA, et al. Among authors: sood ak. Mol Cancer Ther. 2015 Dec;14(12):2677-86. doi: 10.1158/1535-7163.MCT-14-0630. Epub 2015 Oct 29. Mol Cancer Ther. 2015. PMID: 26516159 Free PMC article.

2

Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.

Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, Benda JA, Morgan LS. Sood AK, et al. Cancer. 1998 May 1;82(9):1731-7. Cancer. 1998. PMID: 9576296

3

The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy.

Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJ. Sood AK, et al. Cancer Biol Ther. 2002 Nov-Dec;1(6):661-4. doi: 10.4161/cbt.316. Cancer Biol Ther. 2002. PMID: 12642690 Free article.

4

Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.

Hsu Y, Sood AK, Sorosky JI. Hsu Y, et al. Among authors: sood ak. Am J Clin Oncol. 2004 Feb;27(1):14-8. doi: 10.1097/01.coc.0000045849.95834.6b. Am J Clin Oncol. 2004. PMID: 14758127

5

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.

Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sood AK, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6080-5. doi: 10.1158/1078-0432.CCR-04-0574. Clin Cancer Res. 2004. PMID: 15447993 Clinical Trial.

6

Fifth International Conference on Ovarian Cancer: challenges and opportunities.

Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM. Sood AK, et al. Gynecol Oncol. 2005 Jun;97(3):916-23. doi: 10.1016/j.ygyno.2005.03.013. Gynecol Oncol. 2005. PMID: 15907981

7

Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004.

Sood AK, Coleman RL, Wolf JK, Gershenson DM. Sood AK, et al. Expert Opin Pharmacother. 2005 Jun;6(7):1269-75. doi: 10.1517/14656566.6.7.1269. Expert Opin Pharmacother. 2005. PMID: 15957979 No abstract available.

8

Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.

Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK. Thaker PH, et al. Among authors: sood ak. Clin Cancer Res. 2005 Jul 1;11(13):4923-33. doi: 10.1158/1078-0432.CCR-04-2060. Clin Cancer Res. 2005. PMID: 16000591

9

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Landen CN Jr, et al. Among authors: sood ak. Cancer Res. 2005 Aug 1;65(15):6910-8. doi: 10.1158/0008-5472.CAN-05-0530. Cancer Res. 2005. PMID: 16061675

10

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.

Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Hu L, et al. Among authors: sood ak. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6966-71. doi: 10.1158/1078-0432.CCR-05-0910. Clin Cancer Res. 2005. PMID: 16203789

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,162 results

Search Page

Filters